AR and breast carcinoma: Since AR and androgens increase the proliferation of a molecular apocrine breast cancer cell line, MDA-MB-453, it is widely perceived, albeit falsely, that AR is an unfavorable therapeutic target and prognostic marker in molecular apocrine subtype [33,34].